reported 18 per cent growth in consolidated revenue for the quarter ended March 2026 (Q4FY26) at ₹6,605 crore, with broad-based growth across the hospitals, diagnostics and digital health segments. Net profit for the quarter grew 36 per cent YoY to ₹529 crore.
For the full financial year, consolidated revenue grew 16 per cent YoY to ₹25,229 crore. Consolidated net profit grew 34 per cent YoY to ₹1,942 crore.
The board, in its meeting on Wednesday, also approved plans to combine Apollo Cradle & Fertility with Cloudnine, subject to CCI approval, to create a large maternity and fertility care entity. Under this, AHLL will divest its stake in Apollo Specialty Hospitals Pvt Ltd (ASHPL) and Apollo Fertility Centre Pvt Ltd (AFCPL) to Kids Clinic India (the company behind Cloudnine). The value of the transaction will be ₹1,550 crore and will be executed through a combination of cash and 9.9 per cent stake in the combined entity.
Speaking to businessline, Dr. Madhu Sasidhar, President and CEO, Hospitals Division, Apollo, and Krishnan Akhileswaran, Group CFO, said all business segments and all markets have shown robust growth in the fiscal. The EBITDA margin of established hospital units stood at 25.5 per cent in Q4FY26 versus 24.4 per cent in Q4FY25, Akhileswaran said. “In Q4FY26, the cash burn in our online business was also down indicating operational efficiencies,” he added.
On international business, Dr Sasidhar said that international business from Bangladesh is almost back to normal levels and they have not seen much of an impact on international patients inflow due to the West Asia war.
Healthcare revenue for FY26 stood at ₹12,555 crore, a 13 per cent YoY growth. The retail healthcare and diagnostics arm, Apollo Health and Lifestyle, recorded 20 per cent revenue growth in the fiscal, and also narrowed its losses to ₹10 crore in FY26 versus loss of ₹27 crore in FY25. Digital health arm Apollo HealthCo grew revenue at 19 per cent YoY in FY26, and net profit stood at ₹324 crore vs ₹47 crore in FY25.
As for the scheme to demerge the pharmacy and digital health business and separately list it, the management expects it to close by the fourth quarter of FY27.